Position in CADL
as of Mar 31, 2026
· filed Apr 28, 2026
Position Value
$223,459
New position
Shares Held
45,604
first reported quarter
Ownership
0.062%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Position in Biotechnology
Healthcare · as of Mar 31, 2026Belpointe Asset Management LLC holds $7,054,376 across 13 Biotechnology names. CADL ranks #9 (3.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | MRNA |
Moderna, Inc.
|
34,042 | $1,729,333 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
2,213 | $1,709,852 | |
| 3 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
2,776 | $1,239,595 | |
| 4 | HALO |
Halozyme Therapeutics, Inc.
|
15,088 | $975,137 | |
| 5 | SPRY |
ARS Pharmaceuticals, Inc.
|
38,445 | $308,713 | |
| 6 | GALT |
Galectin Therapeutics Inc
|
106,139 | $296,127 | |
| 7 | INCY |
Incyte Corp
|
2,742 | $258,077 | |
| 8 | KLRS |
Kalaris Therapeutics, Inc.
|
40,000 | $230,800 |
All Filings in CADL
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $223,459 | 45,604 | Shares | Sole | 2026-04-28 | |
| No filing history on record for this holder in this stock. | ||||||